EUVIMEDEUVIMED entdecken
Crossref

Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach

Zhengguang Zhang, Tianming Lu, Zhe Zhang, Zixian Liu, Ruoning Qian, Ruogu Qi, Fuqiong Zhou, Min Li

Biochemical Pharmacology · 2024-04 · 222 · 116117

DOI: 10.1016/j.bcp.2024.116117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024-04. Verfasst von Zhengguang Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China. Electronic address: zhengguangzhang@njucm.edu.cn. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Colorectal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Nanjing University of Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oxaliplatin (OXA) is a platinum-based chemotherapeutic agent with promising applications in the treatment of various malignancies, particularly colorectal cancer (CRC). However, the management of OXA resistance remains an ongoing obstacle in CRC therapy. This study aims to comprehensively investigate the immune landscape, targeted therapeutic biomarkers, and mechanisms that influence OXA resistance in CRC. Our results demonstrated that our OXA- resistant CRC prognostic model not only provides risk assessment for patients but also reflects the immune landscape of patients. Additionally, we identified prostate transmembrane protein, androgen-induced1 (PMEPA1) as a promising molecular targeted therapeutic biomarker for patients with OXA-resistant CRC. The mechanism of PMEPA1 may involve cell adhesion, pathways in cancer, and the TGF-β signaling pathway. Furthermore, analysis of CRC clinical samples indicated that patients resistant to OXA exhibited elevated serum levels of TGF-β1, increased expression of PMEPA1 in tumors, a lower proportion of CD8+ T cell positivity, and a higher proportion of M0 macrophage positivity, in comparison to OXA-sensitive individuals. Cellular experiments indicated that selective silencing of PMEPA1, alone or in combination with OXA, inhibited proliferation and metastasis in OXA-resistant CRC cells, HCT116R. Animal experiments further confirmed that PMEPA1 silencing suppressed subcutaneous graft tumor growth and liver metastasis in mice bearing HCT116R and synergistically enhanced the efficacy of OXA. These data highlight the potential of leveraging the therapeutic biomarker PMEPA1, CD8+ T cells, and M0 macrophages as innovative targets for effectively addressing the challenges associated with OXA resistance. Our findings hold promising implications for further clinical advancements in this field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesColorectal NeoplasmsMaleHumansAnimalsMiceOxaliplatinBiomarkersCell Line, TumorMembrane Proteins

Stichwörter der Autor:innen

Colorectal cancerImmune landscapeOxaliplatin resistanceProstate transmembrane protein, androgen-induced1

Substanzen

OxaliplatinBiomarkersPMEPA1 protein, humanMembrane Proteins

Autor:innen und Institutionen

  • School of Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China. Electronic address: zhengguangzhang@njucm.edu.cn.
  • School of Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China.
  • Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China.
  • School of Medicine, Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China. Electronic address: rqi@njucm.edu.cn.
  • Central Laboratory, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China. Electronic address: zhoufuqiong@njucm.edu.cn.
  • Department of Oncology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Jiangsu, Nanjing, China. Electronic address: fsyy00340@njucm.edu.cn.

Förderung

  • Nanjing University of Chinese Medicine

Zitieren

APA

Zhang, Z., Lu, T., Zhang, Z., Liu, Z., Qian, R., Qi, R., Zhou, F., & Li, M. (2024). Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach. Biochemical Pharmacology, 222, 116117. https://doi.org/10.1016/j.bcp.2024.116117

Vancouver

Zhang Z, Lu T, Zhang Z, Liu Z, Qian R, Qi R, et al. Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach. Biochemical Pharmacology. 2024;222:116117. doi:10.1016/j.bcp.2024.116117

BibTeX
@article{Zhang2024,
  author = {Zhang, Zhengguang and Lu, Tianming and Zhang, Zhe and Liu, Zixian and Qian, Ruoning and Qi, Ruogu and Zhou, Fuqiong and Li, Min},
  title = {Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach},
  journal = {Biochemical Pharmacology},
  year = {2024},
  volume = {222},
  pages = {116117},
  doi = {10.1016/j.bcp.2024.116117}
}
Kostenlos starten →